Tesamorelin

TESAMORELIN

Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release endogenous growth hormone (GH). It increases circulating insulin-like growth factor 1 (IGF-1), leading to enhanced lipolysis, protein synthesis, and tissue repair. Clinically, Tesamorelin is FDA-approved for the treatment of HIV-associated lipodystrophy, where it reduces visceral adiposity and improves metabolic profiles. It is also under investigation for age-related GH decline, cognitive protection, and hepatic steatosis due to its effects on lipid metabolism and mitochondrial function.

No results